Akero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH obliterated expectations. SAN FRANCISCO, Jan. 27, 2025 (GLOBE NEWSWIRE ...

SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and ...

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

Shares of ETNB opened at $8.47 on Friday. 89bio has a 52 week low of $5.99 and a 52 week high of $13.71. The company has a quick ratio of 11.66, a current ratio of 11.66 and a debt-to-equity ratio ...

After hours: 6:15:15 p.m. EDT Loading Chart for ETNB ...

Citigroup assumed coverage on shares of 89bio (NASDAQ:ETNB – Free Report) in a report released on Thursday morning, Marketbeat reports. The brokerage issued a buy rating and a $25.00 target ...

Californian biotech 89bio has joined the small group of drugmakers with proof-of-concept clinical results in the fatty liver disease non-alcoholic steatohepatitis (NASH), encouraging enough for it ...